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toward jettisoning the notion that “children are little adults.” It
is now well recognized that children’s unique patterns of health
and disease, growth and development, and dependency on adults
for managing their health provide strong justiﬁcation for the ﬁeld
of pediatric research [1]. The types, manifestations, and fre-
quency of various diseases as well as the adverse event proﬁle
for medical treatments can differ between adults and children,
and sadly conditions such as hypertension and metabolic syn-
drome once considered adult-onset have inﬁltrated childhood.
Maturation of children’s physiology inﬂuences the qualitative
and quantitative effects of medical products, which calls into
question the use of “hand-me-down” [2] results from medical
product studies done among adults. Particularly for infants and
young children we rely on parents and caregivers to implement
treatments and to provide their observations on treatment
effects.
Recognition of the unique attributes of childhood that merit a
special research focus is relatively new. A 1996 workshop held
jointly by the American Academy of Pediatrics and the National
Institute of Child Health and Human Development concluded
that approximately 15% of research studies had inappropriately
excluded children. This deﬁciency was a key reason why the
National Institutes of Health issued guidelines in 1998 on the
inclusion of children in clinical research [3]. At about the same
time, Congress passed the Food Drug Administration Moderniza-
tion Act that offered an additional 6 months of market exclusivity
to pharmaceutical companies for conducting pediatric studies [4].
Many drugs continue to receive pediatric labeling under this
provision. Today, the Best Pharmaceuticals for Children Act and
the Pediatric Research Equity Act provide a regulatory infrastruc-
ture comprising incentives and requirements intended to
increase the amount of medical product research done on
children and adolescents [5].
During the same interval that children in clinical studies were
receiving more attention, the use of patient-reported outcomes
(PROs) in research proliferated. The 2009 guidance issued by the
Food and Drug Administration on necessary criteria for using
PROs to support medical product labeling [6], the federal govern-
ment’s establishment of the Patient-Centered Outcomes
Research Institute [7], and the National Institute of Health’s
Patient Reported Outcome Measurement Information System [8]
are important accelerators for the adoption of PROs into the
clinical research enterprise. New guidelines for selecting PROs [9]
and reporting PRO results [10] have been produced to strengthen
the quality of the rapidly growing knowledge base that has
accrued as a result of the inclusion of PROs in studies.
Anticipating the dual trends in greater pediatric clinical
research and use of PROs as clinical end points, ISPOR convenedan expert panel to develop best practice recommendations for
using pediatric PROs in medical product labeling [11]. The author-
ship team responsible for these good research practices has
produced a tour de force. Nowhere else in the literature can a
reader ﬁnd such a detailed compendium of evidence regarding
the unique challenges associated with collecting PRO data from
children, the evidence base for the reliability and validity of
children’s self-reported health assessments, and a synthesis of
the future research that is needed to advance the ﬁeld. The article
is intended to address the use of pediatric PROs for medical
product labeling, but this is a minor limitation in scope. Any
clinical researcher who uses PROs in child and adolescent
populations will ﬁnd the work to be immensely helpful.
The ISPOR Task Force Report provided an overview of the self-
report skills that are needed to respond to questionnaires. To
reliably and validly complete health questionnaires, a respondent
must be able to read questions (or comprehend questions read
aloud), understand the meaning of health terms, and formulate
responses that account for the recall period. We know remark-
ably little about the developmental trajectories of these skills.
PRO researchers use cognitive interviewing methods to evaluate
children’s self-report capabilities. The validity of these methods
for children, whose expressive language may lag their receptive
language skills, however, is not well established; respondents
who understand an item may be unable to verbalize reasons for
their response choices. We also lack guidance on how many
children of a particular age need to be interviewed to have
sufﬁcient information to ensure that when the items are used
in the general population they will accurately assess the target
health concepts. Research is needed, as Matza et al. [11] sug-
gested, that develops and evaluates tools and methods for PRO
completion skill screening. Such a skills assessment system
would enable alteration of PRO mode of administration and
perhaps scale content on the basis of an individual’s cognitive
skills rather than calendar age, moving the ﬁeld (appropriately)
away from age-based to stage-based PRO assessment.
Human development is a set of processes and mechanisms,
rather than end states or skills. Development describes the
pathways that result from individuals’ dynamic and relational
interactions with their environments, thereby leading to the
formation of new capabilities and functional capacities. Impor-
tantly, human development transpires over the entire life course.
It strikes me as odd that developmental considerations have been
relegated to pediatric research. Cognitive skills may not develop
in some adults, nearly one in four have low literacy, and in later
years, skills may decline. We treat the age range 18 to 85 years as
though it is a single, monolithic developmental stage of life.
Adult PRO research could be strengthened by adding a develop-
mental framework that not only addresses cognitive skills but
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appropriate at each stage of life. Additional considerations that
are important across the life course are the effects of changing
biological, cultural, and contextual inﬂuences on the (develop-
mentally appropriate) content of PRO scales. Developmental
stage is also likely to be a strong determinant of individuals’
preferences and priorities for treatment outcomes. In other
words, the PRO concepts that are important to individuals may
vary across the phases of the life course.
If we limit our view of pediatric PRO assessment to ages 0 to
17 years, then self-report, as the Task Force report indicates, can
be justiﬁed for medical product labeling for only 10 of those 18
years (8–17 years of age). This leaves a large gap in our capacity to
obtain children’s perspectives on their health. Pediatric clinicians
and parents know that children at young ages, even infants, can
communicate feelings and sensations through nonverbal facial
expressions and verbal utterances. As young children acquire
language, we can obtain valuable information by directly inter-
viewing them about their current health states. Creation of PROs
for young children will require that we develop novel methods for
observing their health and eliciting their verbalizations. Frequent
momentary assessments (multiple times per day) [12] hold
promise as a methodology that merits further investigation for
young child PRO assessment.
Another aspect of children’s development related to medical
product labeling is concerned with the late effects of medical
treatments. The developmental origins of chronic disease have
been well established for a variety of chronic and mental health
disorders [13,14]. Given the sensitivity of children’s biology to
environmental inﬂuences, it is plausible, and indeed likely, that
medical products will have long-term effects on child health.
Thus, we need to build data collection systems that evaluate
pediatric PROs not only as immediate outcomes but also as
outcomes that may not manifest themselves until long after
exposure.
Numerous recruitment, ethical, and ﬁnancial barriers to
pediatric clinical research still need to be addressed if we are to
secure the knowledge that children, families, and clinicians need
to make evidence-based decisions about medical products. The
pediatric research regulatory infrastructure in the United States
reﬂects our society’s impatience with the inadequacy of the
medical product evidence base and continued reliance on off-
label use of medical products among children. As the ISPOR Task
Force Report on Pediatric PROs indicates, measurement of chil-
dren’s perspectives on their health has advanced sufﬁciently to
merit the use of pediatric PROs in clinical research and for
medical product claims. The scientiﬁc community has crossed
the threshold from uncertainty regarding children’s capacity to
self-report about their health to an era when child self-reported
health status instruments have been widely adopted by scientists
and integrated into the research enterprise. These advances in
pediatric PRO assessment are ensuring that children’s voices will
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